• Conference Proceeding

Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU)

Citation

Graham, J., McBride, D., Stull, D., Halliday, A., Alexopoulos, S. T., Balp, M., ... Brennan A (2015). Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU). Value in Health, 18(7), A423.

Abstract